Health Economics›Indolent lymphoma›Relapsed or refractory

Relapsed or refractory

Indolent lymphoma · 31 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Obinutuzumab monotherapy Variant #03	—	R 166 941	21d	—	—	—	—	—
Fludarabine and Rituximab (FR) Variant #06	—	R 117 749	28d	—	—	—	—	—
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	~39.4 mo	—	~35	~R 3 036 103 PFS proxy · indirect	1
BVR Variant #02	—	R 69 654	35d	—	—	—	—	—
R-CHOP Variant #23	—	R 59 865	21d	~44.4 mo	—	~65	~R 3 891 219 PFS proxy · indirect	1
Copanlisib and Rituximab Variant #01 Partial	—	R 58 980	28d	~21.5 mo	—	~24	~R 1 415 508 PFS proxy · indirect	1
Lenalidomide, Dexamethasone, Rituximab Variant #01	—	R 50 157	28d	—	—	—	—	—
R-FND Variant #02	—	R 46 106	28d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~34.2 mo	—	~38	~R 1 550 664 PFS proxy · indirect	4
Ibritumomab tiuxetan protocol Variant #18	—	R 27 524	8d	~36.5 mo	—	~139	~R 3 825 804 PFS proxy · indirect	1
R-DexaBEAM Variant #01 Partial	—	R 25 792	28d	—	—	—	—	—
R-INO Variant #01 Partial	—	R 11 796	28d	—	~9.5 mo	—	—	1
Vorinostat and Rituximab Variant #01 Partial	—	R 11 796	21d	—	—	—	—	—
Fludarabine monotherapy Variant #01	—	R 11 691	28d	~16.5 mo	~52.9 mo	~18	~R 210 435 PFS proxy · indirect	4
FMP Variant #01	—	R 10 509	21d	—	—	—	—	—
Bortezomib monotherapy Variant #14	—	R 8 539	35d	~30.3 mo	—	~27	~R 230 565 PFS proxy · indirect	5
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~30.8 mo	—	~11	~R 69 973 PFS proxy · indirect	2
Bendamustine monotherapy Variant #01	—	R 5 419	—	13.8 mo	—	—	—	1
PEP-C Variant #01 Partial	—	R 110	—	—	—	—	—	—
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~17.7 mo	—	~3	~R 156 PFS proxy · indirect	4
Ofatumumab monotherapy N/A - secondary systemic drug	—	R 2	56d	~8.1 mo	—	~5	~R 9 PFS proxy · indirect	4
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	~4.8 mo	~17.2 mo	~6	~R 1 PFS proxy · indirect	3
Axicabtagene ciloleucel monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	1
131Iodine-Tositumomab monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	—
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~15	—	1
Inotuzumab ozogamicin monotherapy Variant #01 Partial	—	—	28d	—	~7.7 mo	—	—	1
Umbralisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Idelalisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Interferon alfa monotherapy Variant #01 Partial	—	—	7d	—	—	—	—	—
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~4	—	1
Copanlisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

31 of 31 regimens shown